Xarelto’s risks outweigh the benefits: Beasley Allen principal David Byrne explains

In this episode of the Beasley Allen Report, host Gibson Vance welcomes fellow Beasley Allen principal David Byrne to speak on a relatively new and dangerous blood thinner on the market, Xarelto.

Xarelto is in a new class of blood thinners designed to be an alternative to warfarin for the treatment of blood clots; however, unlike warfarin, there is no antidote to reverse the blood thinning effects. Despite being approved by the FDA, Xarelto carries many black box warnings, the most serious kind issued by the FDA. The warnings link the drug to an increased risk of blood clots with premature discontinuation of therapy, and a risk of epidural or spinal hematomas resulting in long-term or permanent paralysis in patients treated with Xarelto receiving neuraxial anesthesia or undergoing spinal puncture. Byrne recommends talking to your doctor if you are already taking Xarelto in order to have an honest discussion about concerns and alternative options.

For more information on Xarelto and the firm’s latest legal news, visit Beasley Allen’s website at www.BeasleyAllen.com.


We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

xarelto

Plaintiffs continue seeking justice over Xarelto...

Less than three years after Xarelto’s initial approval, the FDA issued black box warnings because of...
xarelto

New, contradictory evidence from Xarelto makers could...

There is an effective lab test to protect patients taking Xarelto, but that isn’t what jurors heard...
xarelto

Third Xarelto Trial Begins This Week

Last month, U.S. District Judge Eldon E. Fallon rejected the latest attempts by Xarelto makers to dodge...
xarelto

Recent studies confirm Xarelto bleeding risks, adverse...

There were 21,996 severe injuries reported involving anticoagulant drugs including 3,018 reported...
xarelto

Second Xarelto bellwether trial underway

The second bellwether trial involving bleeding risks with the blood thinner Xarelto is slated to begin...
xarelto

First Xarelto trial set for April; blood thinner...

The first of four bellwether trials for the Xarelto multidistrict litigation (MDL) is set to begin on...

A special thanks

A special thanks to your law firm and staff for all the work done on the Vioxx case. The settlement could not have come at a better time for my family and myself. I thank you for a job well done!

—George